Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine.
about
Immunology of Gut Mucosal VaccinesThe nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice.Regulation of Vi capsular polysaccharide synthesis in Salmonella enterica serotype TyphiShigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.Gut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans.Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adultsMolecular cloning and characterization of genes for Shigella sonnei form I O polysaccharide: proposed biosynthetic pathway and stable expression in a live salmonella vaccine vectorEnhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a LPS vaccinesRoom temperature stabilization of oral, live attenuated Salmonella enterica serovar Typhi-vectored vaccines.Serum antibody to lipopolysaccharide antigens of Shigella species among U.S. military personnel deployed to Saudi Arabia and Kuwait during Operations Desert Shield and Desert Storm.Antibody and cytokine responses in a mouse pulmonary model of Shigella flexneri serotype 2a infection.Recognition of three epitopic regions on invasion plasmid antigen C by immune sera of rhesus monkeys infected with Shigella flexneri 2a.Development of Shigella sonnei live oral vaccines based on defined rfbInaba deletion mutants of Vibrio cholerae expressing the Shigella serotype D O polysaccharide.Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.Role of RpoS in fine-tuning the synthesis of Vi capsular polysaccharide in Salmonella enterica serotype TyphiLocal immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.Enteric pathogens as vaccine vectors for foreign antigen deliveryShigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice.Recombinant avirulent salmonellae as oral vaccine carriers.Characterization of the rfc region of Shigella flexneri.Development of an Acid-Resistant Salmonella Typhi Ty21a Attenuated Vector For Improved Oral Vaccine Delivery.Live-attenuated Shigella vaccines.Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21aSpecific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonneiSmall-animal model to measure efficacy and immunogenicity of Shigella vaccine strains.Oral immunization of rabbits with enterotoxigenic Escherichia coli protects against intraintestinal challenge.Establishment of a Shigella sonnei human challenge model in Thailand.Antigen-specific B memory cell responses to lipopolysaccharide (LPS) and invasion plasmid antigen (Ipa) B elicited in volunteers vaccinated with live-attenuated Shigella flexneri 2a vaccine candidatesAdjuvants.Human challenge studies: a review of adequacy of reporting methods and results.The Shigella human challenge model.The Orchestra and Its Maestro: Shigella's Fine-Tuning of the Inflammasome Platforms.Immunization of Mice with a Live Transconjugant Shigella Hybrid Strain Induced Th1 and Th17 Cell-Mediated Immune Responses and Confirmed Passive Protection Against Heterologous Shigellae.Effect of antipyretic therapy on the duration of illness in experimental influenza A, Shigella sonnei, and Rickettsia rickettsii infections.Immunoglobulin subclass distribution and dynamics of Shigella-specific antibody responses in serum and stool samples in shigellosisStable expression of Shigella dysenteriae serotype 1 O-antigen genes integrated into the chromosome of live Salmonella oral vaccine vector Ty21a.Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers.Protective ribosomal preparation from Shigella sonnei as a parenteral candidate vaccine.
P2860
Q28972559-04845D00-EB57-421A-88CB-CAD3D2EA576EQ33877406-46F57195-2B53-424D-B31C-B3843C18A511Q33910337-ABBB8744-7067-460B-AA95-8EEDB06357BBQ34003433-C921F7C5-A58E-4973-8A06-0199095C25E4Q34068059-5C3585FE-88D1-44C3-9478-5BD6B4715DAAQ34120926-468F5891-36C5-4E1F-9C74-5EEF20E321FDQ34129475-2B5543C5-7D9F-4D7E-BC05-D1428FA3DB97Q34546234-81883841-0BEA-45AB-AD8C-22927AFD56B1Q34711665-AAADEB54-A80E-4DF3-B297-EE84FEC766D1Q35225017-35496050-325C-4249-9986-68A62E06F06CQ35411990-024AF8A3-9943-4FB8-B74F-10E70B46D2D7Q35443019-C2E1B7DE-92E1-4A16-9756-49727227FE03Q35469131-900DE0A1-FBB2-4334-8834-A000039BAB9DQ35528270-EEC39FD9-4383-4E3D-B2F5-D8620EFD003FQ35689430-0649A32E-5C12-4BD2-B2AE-7805BED7888FQ35772614-69CAD749-00D3-40CD-B550-B69639F9432FQ35896020-0C506C1D-81D8-44C2-B957-5841B5DA081DQ35946462-3F16A1AB-2E5F-4994-B9C9-8050A9188469Q36002472-84E9C25B-7E04-4D8C-80D3-A3C124B867A6Q36105069-906E1CC2-823E-422E-A30B-A013F8FD6E4FQ36145803-06228834-1314-4B70-A20E-887CCDD1C3EDQ36689023-1DD3F791-5E2A-475D-B19E-895B1D8B290DQ36844719-5DE54149-B068-4D1D-BAB4-F03A6B14F64AQ36945836-ACB128E5-0171-4C0F-9788-2CE59FC7F758Q36982528-74934EF1-1B5A-4D10-9EB5-73DF34FE96DBQ36985066-25EEB404-351A-416E-AEF4-5F1F38819A2FQ36989057-EF6FB929-0F34-451B-A474-111B4D31232DQ36993634-3792E932-ECA6-411A-916A-826DF17E6533Q37066116-D7633FC5-6067-4F3C-9899-14475BE159CAQ37120727-F4D8B359-C88B-4717-813B-BF15C3644F08Q37844069-8F517258-6775-46A0-A548-30C097749626Q37996090-072D4D6C-712E-4100-B72D-E518502656A7Q38035961-1E378473-7A84-4099-B598-C014BF4016BBQ38909275-FFBA0430-17DA-4D94-9CB5-912565584FE9Q38952300-E344CD58-6836-45EA-9F13-6B2C8DF81EA3Q39423812-4A7BF454-5DE2-4D51-A705-1E9C2107C388Q39822100-84FB2A1E-DB2A-4D26-B87A-C81AB1FFF528Q40087889-756E4AC1-124E-420E-9BA8-FE3FF91E8456Q40149266-03524CB6-81F0-44E8-8320-0A55ED73180CQ40155606-A08C5C01-5C03-4ED7-B0C1-A0974C93EDE7
P2860
Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh-hant
name
Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine.
@en
Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine.
@nl
type
label
Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine.
@en
Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine.
@nl
prefLabel
Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine.
@en
Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine.
@nl
P2093
P356
P1476
Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine.
@en
P2093
Clements ML
Herrington D
Losonsky G
P304
P356
10.1093/INFDIS/155.6.1260
P407
P577
1987-06-01T00:00:00Z